Adage Capital Partners
ADPT icon

Adage Capital Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Adage Capital Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-100,000
Closed -$4.83M – 714
2019
Q2 		$4.83M Buy
+100,000
New +$4.43M 0.01% 617

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Adage Capital Partners's ADPT Position: Q3 2019 in Review

Adage Capital Partners sold out of Adaptive Biotechnologies (ADPT) in Q3 2019, closing a stake of 100,000 shares — an estimated $4.83M sold.

Adage Capital Partners first reported a position in ADPT in Q2 2019 and held it in 1 quarter. The position peaked at $4.83M in Q2 2019. 117 funds tracked by Wall St. Rank hold ADPT as of Q3 2019.

  • Adage Capital Partners reported no remaining Adaptive Biotechnologies position as of Q3 2019 after selling out during the quarter.
  • Adage Capital Partners sold 100,000 Adaptive Biotechnologies shares in Q3 2019, an estimated $4.83M.
  • Adage Capital Partners first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 1 quarter.
  • Adage Capital Partners's Adaptive Biotechnologies position peaked at $4.83M in Q2 2019.
  • 117 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2019.

Based on Adage Capital Partners's 13F filing for Q3 2019, filed 14 Nov 2019.